1 | Anti-von Willebrand Factor Nanobody, Caplacizumab | [2] Caplacizumab Caplacizumab, Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
2 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab | [2] Caplacizumab Caplacizumab, Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
3 | CAPLACIZUMAB | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
4 | Caplacizumab (ALX-0081) | [1] Caplacizumab Caplacizumab | [1] Caplacizumab
Caplacizumab
💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
5 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) | [2] Caplacizumab Caplacizumab, Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|
6 | Caplacizumab (an anti-von Willebrand Factor Nanobody) | [2] Caplacizumab Caplacizumab, Von Willebrand factor human | [1] Caplacizumab
Caplacizumab
💬
| [1] VWF VWF 💬
| [8] Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 | [1] 64 64 💬
|